Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1946 1
1947 2
1951 3
1952 4
1953 1
1954 5
1955 2
1958 1
1960 1
1961 1
1962 1
1963 3
1965 1
1966 1
1967 2
1968 5
1969 3
1970 1
1971 1
1972 2
1973 2
1974 4
1976 6
1977 4
1978 8
1979 3
1980 6
1981 5
1982 5
1983 1
1984 4
1985 2
1986 4
1987 7
1988 7
1989 10
1990 5
1991 5
1992 3
1993 1
1994 5
1995 8
1996 4
1997 10
1998 7
1999 10
2000 13
2001 6
2002 5
2003 13
2004 14
2005 8
2006 13
2007 11
2008 13
2009 15
2010 18
2011 29
2012 28
2013 29
2014 22
2015 33
2016 24
2017 36
2018 40
2019 36
2020 44
2021 46
2022 34
2023 29
2024 15

Text availability

Article attribute

Article type

Publication date

Search Results

688 results

Results by year

Filters applied: . Clear all
Page 1
Phase II Randomized Trial of Transoral Surgery and Low-Dose Intensity Modulated Radiation Therapy in Resectable p16+ Locally Advanced Oropharynx Cancer: An ECOG-ACRIN Cancer Research Group Trial (E3311).
Ferris RL, Flamand Y, Weinstein GS, Li S, Quon H, Mehra R, Garcia JJ, Chung CH, Gillison ML, Duvvuri U, O'Malley BW Jr, Ozer E, Thomas GR, Koch WM, Gross ND, Bell RB, Saba NF, Lango M, Méndez E, Burtness B. Ferris RL, et al. Among authors: gross nd. J Clin Oncol. 2022 Jan 10;40(2):138-149. doi: 10.1200/JCO.21.01752. Epub 2021 Oct 26. J Clin Oncol. 2022. PMID: 34699271 Free PMC article. Clinical Trial.
Neoadjuvant Cemiplimab for Stage II to IV Cutaneous Squamous-Cell Carcinoma.
Gross ND, Miller DM, Khushalani NI, Divi V, Ruiz ES, Lipson EJ, Meier F, Su YB, Swiecicki PL, Atlas J, Geiger JL, Hauschild A, Choe JH, Hughes BGM, Schadendorf D, Patel VA, Homsi J, Taube JM, Lim AM, Ferrarotto R, Kaufman HL, Seebach F, Lowy I, Yoo SY, Mathias M, Fenech K, Han H, Fury MG, Rischin D. Gross ND, et al. N Engl J Med. 2022 Oct 27;387(17):1557-1568. doi: 10.1056/NEJMoa2209813. Epub 2022 Sep 12. N Engl J Med. 2022. PMID: 36094839 Free PMC article. Clinical Trial.
Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma.
Amaria RN, Reddy SM, Tawbi HA, Davies MA, Ross MI, Glitza IC, Cormier JN, Lewis C, Hwu WJ, Hanna E, Diab A, Wong MK, Royal R, Gross N, Weber R, Lai SY, Ehlers R, Blando J, Milton DR, Woodman S, Kageyama R, Wells DK, Hwu P, Patel SP, Lucci A, Hessel A, Lee JE, Gershenwald J, Simpson L, Burton EM, Posada L, Haydu L, Wang L, Zhang S, Lazar AJ, Hudgens CW, Gopalakrishnan V, Reuben A, Andrews MC, Spencer CN, Prieto V, Sharma P, Allison J, Tetzlaff MT, Wargo JA. Amaria RN, et al. Among authors: gross n. Nat Med. 2018 Nov;24(11):1649-1654. doi: 10.1038/s41591-018-0197-1. Epub 2018 Oct 8. Nat Med. 2018. PMID: 30297909 Free PMC article. Clinical Trial.
Neoadjuvant Cabozantinib and Nivolumab Converts Locally Advanced HCC into Resectable Disease with Enhanced Antitumor Immunity.
Ho WJ, Zhu Q, Durham J, Popovic A, Xavier S, Leatherman J, Mohan A, Mo G, Zhang S, Gross N, Charmsaz S, Lin D, Quong D, Wilt B, Kamel IR, Weiss M, Philosophe B, Burkhart R, Burns WR, Shubert C, Ejaz A, He J, Deshpande A, Danilova L, Stein-O'Brien G, Sugar EA, Laheru DA, Anders RA, Fertig EJ, Jaffee EM, Yarchoan M. Ho WJ, et al. Among authors: gross n. Nat Cancer. 2021 Sep;2(9):891-903. doi: 10.1038/s43018-021-00234-4. Epub 2021 Jul 29. Nat Cancer. 2021. PMID: 34796337 Free PMC article. Clinical Trial.
Profiling of syngeneic mouse HCC tumor models as a framework to understand anti-PD-1 sensitive tumor microenvironments.
Zabransky DJ, Danilova L, Leatherman JM, Lopez-Vidal TY, Sanchez J, Charmsaz S, Gross NE, Shin S, Yuan X, Hernandez A, Yang H, Xavier S, Shu D, Saeed A, Munjal K, Kamdar Z, Kagohara LT, Jaffee EM, Yarchoan M, Ho WJ. Zabransky DJ, et al. Among authors: gross ne. Hepatology. 2023 May 1;77(5):1566-1579. doi: 10.1002/hep.32707. Epub 2023 Apr 17. Hepatology. 2023. PMID: 35941803 Free PMC article.
In Reply.
Bennett CL, Raja AS, Kass D, Gross N, Mills AM. Bennett CL, et al. Among authors: gross n. Acad Emerg Med. 2019 Nov;26(11):1303. doi: 10.1111/acem.13828. Epub 2019 Jul 24. Acad Emerg Med. 2019. PMID: 31286614 Free article. No abstract available.
Evaluation of Overall Survival in Patients With Anaplastic Thyroid Carcinoma, 2000-2019.
Maniakas A, Dadu R, Busaidy NL, Wang JR, Ferrarotto R, Lu C, Williams MD, Gunn GB, Hofmann MC, Cote G, Sperling J, Gross ND, Sturgis EM, Goepfert RP, Lai SY, Cabanillas ME, Zafereo M. Maniakas A, et al. Among authors: gross nd. JAMA Oncol. 2020 Sep 1;6(9):1397-1404. doi: 10.1001/jamaoncol.2020.3362. JAMA Oncol. 2020. PMID: 32761153 Free PMC article.
Neoadjuvant Approaches to Non-Melanoma Skin Cancer.
Wilde DC, Glaun ME, Wong MK, Gross ND. Wilde DC, et al. Among authors: gross nd. Cancers (Basel). 2023 Nov 21;15(23):5494. doi: 10.3390/cancers15235494. Cancers (Basel). 2023. PMID: 38067198 Free PMC article. Review.
Neoadjuvant cemiplimab and surgery for stage II-IV cutaneous squamous-cell carcinoma: follow-up and survival outcomes of a single-arm, multicentre, phase 2 study.
Gross ND, Miller DM, Khushalani NI, Divi V, Ruiz ES, Lipson EJ, Meier F, Su YB, Swiecicki PL, Atlas J, Geiger JL, Hauschild A, Choe JH, Hughes BGM, Schadendorf D, Patel VA, Homsi J, Taube JM, Lim AM, Ferrarotto R, Yoo SY, Mathias M, Han H, Seebach F, Lowy I, Fury MG, Rischin D. Gross ND, et al. Lancet Oncol. 2023 Nov;24(11):1196-1205. doi: 10.1016/S1470-2045(23)00459-X. Epub 2023 Oct 21. Lancet Oncol. 2023. PMID: 37875144 Clinical Trial.
688 results